ArticleNPJ precision oncology2026
Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Effective management of advanced epithelial ovarian cancer (EOC) is challenging, with most patients relapsing despite standard therapies, highlighting the need for personalized treatment. Functional ex vivo drug testing enables matching patients to effective therapies based on drug sensitivity. We present DRUGSENS, a scalable, clinically adaptable ex vivo screening platform that quantitatively assesses single-cell, on-target drug effects in cell lines and patient-derived samples. DRUGSENS offers high-resolution analysis of responses to single agents and relevant drug combinations, guiding personalized treatment across tumor types. The semi-automated assay integrates immunofluorescence-based confocal imaging with computational analysis using QuPath, Fiji, and a dedicated R package. We profiled 21 samples from 17 patients in chemotherapy-naive and relapsed states, achieving 100% culture success and delivering results within 10 days. Most samples showed limited sensitivity to multiple agents, indicating multidrug resistance. Notably, ex vivo drug responses correlated significantly with progression-free and overall survival. DRUGSENS supports rapid, clinically relevant functional profiling in EOC, providing a valuable tool to inform treatment recommendations and prioritize drugs for clinical application.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.